Bayer terminates Ovaprene license; Daré regains full rights, Phase 3 study continues

Dare Bioscience, Inc.

Bayer HealthCare terminated Ovaprene license agreement effective Feb 24, 2026 due to strategic prioritization.
Daré regains full commercialization rights to Ovaprene, a hormone-free monthly intravaginal contraceptive.
Pivotal Phase 3 study continues with positive interim data (July 2025) and Gates Foundation grant support.
Enrollment expected to complete in 2026; no change to timelines or operations.
Daré to explore partnerships and strategic transactions for Ovaprene.

item 1.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Dare Bioscience, Inc. terminated License Agreement with Bayer HealthCare LLC (effective 2026-02-24).

Action: termination
Agreement: license
Counterparty: Bayer HealthCare LLC
Effective: 2026-02-24

Exact text from the filing

On November 26, 2025, Daré Bioscience, Inc. (“we,” “us”, “our,” or the “Company”) received notice from Bayer HealthCare LLC (“Bayer”) that it was terminating the license agreement between the parties dated January 10, 2020 (the “License Agreement”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-025491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.